Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285926 | 0.88 | KMT2A (0.66) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2285474 | 0.86 | KMT2A (0.66) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2290789 | 0.85 | KMT2A (0.65) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2288885 | 0.85 | KMT2A (0.65) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2288665 | 0.79 | MAPT (0.62) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2288145 | 0.77 | KMT2A (0.60) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2290809 | 0.77 | KMT2A (0.60) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL15520341 | 0.75 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2289155 | 0.73 | KMT2A (0.66) | SMN1; SMN2LMNARAB9ANPC1GAA | |
| SCHEMBL2288920 | 0.72 | KMT2A (0.62) | SMN1; SMN2LMNARAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | claimed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | claimed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7786171-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2119476-A2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | SMN1; SMN2 1018/4885LMNA 4622/4885RAB9A 1798/4885 |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | SMN1; SMN2 1018/4885LMNA 4622/4885RAB9A 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.